AllianceBernstein
ROIV icon

AllianceBernstein’s Roivant Sciences ROIV Stock Holding History

AllianceBernstein’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Sell
550,827
-125,517
-19% -$3.71M 0.01% 1032
2026
Q1 		$14.7M Buy
676,344
+134,297
+25% +$3.45M ﹤0.01% 1045
2025
Q4 		$11.8M Sell
542,047
-14,756
-3% -$291K ﹤0.01% 1169
2025
Q3 		$8.42M Buy
556,803
+14,618
+3% +$181K ﹤0.01% 1289
2025
Q2 		$6.11M Sell
542,185
-37,260
-6% -$404K ﹤0.01% 1393
2025
Q1 		$5.85M Buy
579,445
+52,337
+10% +$566K ﹤0.01% 1394
2024
Q4 		$6.24M Buy
527,108
+2,807
+0.5% +$33.2K ﹤0.01% 1388
2024
Q3 		$6.05M Buy
524,301
+76,068
+17% +$866K ﹤0.01% 1433
2024
Q2 		$4.74M Sell
448,233
-20,047
-4% -$220K ﹤0.01% 1510
2024
Q1 		$4.94M Buy
468,280
+372,191
+387% +$4.01M ﹤0.01% 1470
2023
Q4 		$1.08M Buy
96,089
+10,359
+12% +$101K ﹤0.01% 2235
2023
Q3 		$1M Buy
85,730
+3,312
+4% +$37.4K ﹤0.01% 2248
2023
Q2 		$831K Buy
+82,418
New +$737K ﹤0.01% 2373

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AllianceBernstein's ROIV Position: Q2 2026 in Review

AllianceBernstein reduced its Roivant Sciences (ROIV) stake by 19% in Q2 2026, selling an estimated $3.71M and leaving 550,827 shares worth $15.3M. The position accounts for 0.01% of the portfolio, ranked #1032.

AllianceBernstein first reported a position in ROIV in Q2 2023 and has held it in 13 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • AllianceBernstein held 550,827 shares of Roivant Sciences worth $15.3M as of Q2 2026.
  • AllianceBernstein sold 125,517 Roivant Sciences shares in Q2 2026, an estimated $3.71M.
  • Roivant Sciences made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #1032 holding.
  • AllianceBernstein first reported a position in Roivant Sciences in Q2 2023 and has held it in 13 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.